psychedelic-medicine
(6)
The Treatment Was Promising. The Evidence Wasn’t Enough.
Lykos tried to turn a psychedelic therapy born in nonprofit research into a prescription treatment for PTSD. Its FDA setback showed how much more a promising result must prove before it becomes medicine.
The Psychedelic Fund That Grew Into a Bet on the Whole Brain
PsyMed Ventures started with a podcast and a narrow question about psychedelic medicine. Six years later, its portfolio makes a broader wager: that the next important health companies will treat the brain as biology, data and lived experience at once.
The Tiny VC Fund Betting That Health, Food and Climate Are One Problem
Delphi treats a mushroom farm, a digital clinic and a psychedelic drug developer as pieces of the same puzzle: how to finance a healthier relationship between people and the planet.
Journey Clinical
Journey Clinical is a New York-based healthtech company that operates a collaborative-care platform enabling licensed psychotherapists to offer Ketamine-Assisted Psychotherapy (KAP) inside their own private practices. Its in-house medical team handles patient eligibility, ketamine prescriptions, and ongoing medical monitoring, while therapists deliver the preparation, dosing, and integration sessions. The model expands safe, legal access to psychedelic-assisted care for patients with depression, anxiety, PTSD, and other conditions, and has grown to a network of over 2,500 trained providers.
Wonder Sciences
Wonder Sciences is a Los Angeles-based mental health and research company reengineering psychiatric care through psychedelic medicine, clinical research, and AI. Best known for its consumer brand Wondermed - an at-home, low-dose ketamine-assisted telehealth protocol for anxiety and depression - the company is building an AI-native clinical operating system that fuses medication, therapy, and behavioral data into actionable insights. Founded by Ryan Magnussen in 2022, it raised roughly $4.6M-$5.6M in seed funding from investors including Aubrey Marcus and James Foster.
Katie Hanson
Katie Hanson is a strategic operator at the seam between health, AI, and regenerative systems. As Chief Business Officer at Wonder Sciences, she helps move next-generation mental healthcare protocols from research into the real world; as Partner at The Liminal Collective and advisor to organizations from Oceanic Global to Earth 300, she works across the rare overlap of healthspan, climate, and frontier technology.